secwatch.observer — SEC 8-K summary
======================================

Issuer:     MEDIFAST INC (MED)
CIK:        0000910329
Form:       8-K
Filed at:   2026-08-03T20:12:19+00:00
Accession:  0001628280-26-051845
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medifast Q2 2026 revenue $76.4M (-27.6% YoY), net loss $3.1M; guides Q3 rev $60-80M
--------------------------------------------------------------------------------

- Revenue $76.4M, down 27.6% YoY; net loss $3.1M ($0.28 loss per share) vs net income $2.5M ($0.22 EPS) in Q2 2025.
- Active earning coaches 11,700, down 48.7% YoY; revenue per active earning coach $6,529, up 41% YoY.
- Gross profit margin 69.9% vs 72.6% YoY; SG&A as % of revenue 75.6% vs 73.6%.
- Cash and investments $169.8M, no debt; working capital $160.5M.
- Q3 2026 revenue guidance $60-80M, loss per share $0.15-0.65; full year 2026 revenue $270-300M, loss per share $0.25-1.75.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/910329/000162828026051845/0001628280-26-051845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/910329/000162828026051845/med-20260803.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-051845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer